Clinical Trial

A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 3, 2026 (before its estimated July 29, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects
Trial Details
NCT Number NCT07445815
Lead Sponsor Lanzhou Institute of Biological Products Co., Ltd
Conditions Rabies (Healthy Volunteers)
Enrollment 200 participants
Start Date 2026-01-31
Primary Completion 2026-07-29 (estimated)
Study Completion 2026-08-21 (estimated)
Updated on ClinicalTrials.gov 2026-03-03